|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Procter and Gamble |
|---|---|
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002431 |
Purpose
To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients, who are at risk of the disease based on previous history of candidiasis.
| Condition | Intervention |
|---|---|
|
Candidiasis, Oral HIV Infections |
Drug: Chlorhexidine gluconate |
| Study Type: | Interventional |
| Study Design: | Treatment, Dose Comparison |
| Official Title: | A Multi-Center Trial to Evaluate the Safety and Effectiveness of Peridex Dosed Twice or Three Times Daily for Preventing or Delaying the Occurrence of Lesions Due to Oral Candidiasis in HIV-Positive Individuals |
Eligibility| Ages Eligible for Study: | 13 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Prior Medication:
Allowed within 6 months of study entry:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Concurrent Medication:
Excluded:
Concurrent Treatment:
Excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 7 days of study entry:
Prior Treatment:
Excluded within 2 weeks of starting study drug:
Patients must be:
Contacts and Locations| United States, California | |
| Dental Research Institute / UCLA Med Ctr | |
| Los Angeles, California, United States, 900951762 | |
| UCSF / Stomatology Clinical Ctr | |
| San Francisco, California, United States, 94143 | |
| United States, Ohio | |
| Ohio State Univ Hosp Clinic | |
| Columbus, Ohio, United States, 432101228 | |
| United States, Texas | |
| Hermann Hosp / Univ Texas Health Science Ctr | |
| Houston, Texas, United States, 77030 | |
| Bering Dental Clinic | |
| Houston, Texas, United States, 77006 | |
More Information
| Study ID Numbers: | 050A, CC-220 |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002431 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
AIDS-Related Opportunistic Infections chlorhexidine gluconate Acquired Immunodeficiency Syndrome |
Anti-Infective Agents, Local AIDS-Related Complex Candidiasis, Oral |
|
Mouth Diseases Communicable Diseases Anti-Infective Agents Sexually Transmitted Diseases, Viral Candidiasis, Oral Slow Virus Diseases Candidiasis Infection Mycoses Disinfectants Therapeutic Uses Retroviridae Infections Dermatologic Agents |
RNA Virus Infections Chlorhexidine Immune System Diseases Acquired Immunodeficiency Syndrome Immunologic Deficiency Syndromes Pharmacologic Actions Virus Diseases Anti-Infective Agents, Local HIV Infections Chlorhexidine gluconate Sexually Transmitted Diseases Lentivirus Infections Stomatognathic Diseases |